ResMed (RMD) Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RMD shares.
View RMD analyst ratings or view top-rated stocks.

10 Wall Street research analysts have issued 12 month price targets for ResMed's shares. Their RMD share price forecasts range from $180.00 to $290.00. On average, they expect the company's stock price to reach $248.29 in the next twelve months. This suggests a possible upside of 69.1% from the stock's current price.
View analysts price targets for RMD or view top-rated stocks among Wall Street analysts.

ResMed's stock was trading at $208.13 at the start of the year. Since then, RMD stock has decreased by 29.5% and is now trading at $146.83.
View the best growth stocks for 2023 here.

ResMed saw a increase in short interest in September. As of September 15th, there was short interest totaling 3,820,000 shares, an increase of 20.9% from the August 31st total of 3,160,000 shares. Based on an average daily trading volume, of 1,310,000 shares, the days-to-cover ratio is currently 2.9 days.
View ResMed's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our RMD earnings forecast.

ResMed Inc. (NYSE:RMD) announced its quarterly earnings results on Thursday, August, 3rd. The medical equipment provider reported $1.60 earnings per share for the quarter, missing analysts' consensus estimates of $1.67 by $0.07. The medical equipment provider had revenue of $1.12 billion for the quarter, compared to analysts' expectations of $1.14 billion. ResMed had a net margin of 21.25% and a trailing twelve-month return on equity of 24.94%. ResMed's revenue was up 22.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.49 EPS.
Read the conference call transcript.

ResMed announced a quarterly dividend on Thursday, August 3rd. Investors of record on Thursday, August 17th will be paid a dividend of $0.48 per share on Thursday, September 21st. This represents a $1.92 dividend on an annualized basis and a yield of 1.31%. The ex-dividend date is Wednesday, August 16th. This is an increase from the stock's previous quarterly dividend of $0.44.
Read our dividend analysis for RMD.

ETFs with the largest weight of ResMed (NYSE:RMD) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Motley Fool Mid-Cap Growth ETF (TMFM), Fidelity Digital Health ETF (FDHT), Emerge EMPWR Sustainable Select Growth Equity ETF (EMGC), iShares U.S. Medical Devices ETF (IHI), Simplify Market Neutral Equity Long/Short ETF (EQLS), First Trust Indxx Medical Devices ETF (MDEV) and Capital Group Global Growth Equity ETF (CGGO).

ResMed (NYSE:RMD) pays an annual dividend of $1.92 per share and currently has a dividend yield of 1.41%. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 31.48%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 24.33% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

ResMed's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.33%), State Street Corp (4.35%), WCM Investment Management LLC (2.39%), Geode Capital Management LLC (2.27%), Capital World Investors (1.60%) and Northern Trust Corp (1.10%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Karen Drexler, Kaushik Ghoshal, Lucile Blaise, Michael J Farrell, Michael J Rider, Peter C Farrell, Rajwant Sodhi, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends.

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RMD stock can currently be purchased for approximately $146.83.

ResMed (NYSE:RMD) has a market capitalization of $21.59 billion and generates $4.22 billion in revenue each year. The medical equipment provider earns $897.56 million in net income (profit) each year or $6.10 on an earnings per share basis.

The company employs 10,140 workers across the globe.

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The official website for the company is www.resmed.com. The medical equipment provider can be reached via phone at (858) 836-5000, via email at investorrelations@resmed.com, or via fax at 858-836-5501.